Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News Spotlights Stocks

AstraZeneca halts Phase III trials for kidney disease treatment

post-img

AstraZeneca (NASDAQ:AZN) plc has announced the discontinuation of its Phase III STABILIZE-CKD and DIALIZE-Outcomes trials, which were investigating treatments for chronic kidney disease (CKD) due to prolonged enrolment periods and low event rates. Despite this setback, the pharmaceutical giant reaffirms its commitment to addressing hyperkalaemia, a condition commonly associated with CKD, through its globally approved potassium binder, Lokelma.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, assured that Lokelma maintains a strong safety profile and continues to deliver substantial benefits to patients dealing with hyperkalaemia. The drug is currently approved in 56 countries around the world.

AstraZeneca has also committed to ensuring that patients from the halted trials will continue to receive follow-up care. The company’s CVRM (Cardiovascular, Renal and Metabolism) sector remains focused on advancing treatments that protect organs affected by cardiorenal diseases and is working towards the development of regenerative therapies in this field.

Related Post